Evidence map›Paper›PMID 35814626›Full record

ArticleF1000Research2021

Case Report: Recurrent retinal vein occlusion as the first clinical manifestation of systemic lupus erythematosus in a male patient.

Marwa Ben Brahim, Sondes Arfa, Fadia Boubaker, Jihen Chelly, Wafa Ammari, Sonia Hammami, Fatma Arbi, Olfa Berriche

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in F1000Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 67% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Marwa Ben BrahimDepartment of Internal Medicine and Endocrinology, Taher Sfar University Hospital, University of Monastir, Mahdia, 5100, Tunisia.ORCID 0000-0003-1967-0824
Sondes ArfaDepartment of Internal Medicine and Endocrinology, Taher Sfar University Hospital, University of Monastir, Mahdia, 5100, Tunisia.ORCID 0000-0001-7797-4899
Fadia BoubakerDepartment of Internal Medicine and Endocrinology, Taher Sfar University Hospital, University of Monastir, Mahdia, 5100, Tunisia.
Jihen ChellyDepartment of Internal Medicine and Endocrinology, Taher Sfar University Hospital, University of Monastir, Mahdia, 5100, Tunisia.
Wafa AmmariDepartment of Ophthalmology, Taher Sfar University Hospital, University of Monastir, Mahdia, 5100, Tunisia.
Sonia HammamiDepartment of Internal Medicine and Endocrinology, Fattouma Bourguiba University Hospital, University of Monastir, Monastir, 5000, Tunisia.
Fatma ArbiDepartment of Internal Medicine and Endocrinology, Taher Sfar University Hospital, University of Monastir, Mahdia, 5100, Tunisia.
Olfa BerricheDepartment of Internal Medicine and Endocrinology, Taher Sfar University Hospital, University of Monastir, Mahdia, 5100, Tunisia.
University of Monastir · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease characterized by widespread clinical manifestations and immunological disorders. A myriad of ocular manifestations can be seen in patients with SLE. The most vision-threatening complication is vaso-occlusive retinopathy including retinal vein occlusion (RVO). RVO associated with SLE is well described in the literature and its association with antiphospholipid antibodies is recognized. However, RVO as the initial manifestation of SLE is scarcely reported. Herein, we report the first case of recurrent RVO as the revealing manifestation of SLE in a 40-year-old male patient. He had two consecutive episodes of decreased vision. Ophthalmologic examination disclosed a branch retinal vein occlusion the first time and a central retinal vein occlusion the second time. The diagnosis of SLE was established based on clinical and immunological criteria. He was prescribed antiplatelet therapy, hydroxychloroquine at 5.5 mg/kg/day, and intravitreal anti-vascular endothelial growth factor (VEGF) antibodies regimen. He slowly improved under treatment.

Indexed as

Lupus Erythematosus, SystemicRetinal Vein OcclusionAdultHumansMalecase reportIntra-vitreal anti-vascular endothelial growth factor antibodies treatmentMale patientRetinal vein occlusionSystemic Lupus Erythematosus

Identifiers

PMID35814626
PMCPMC9226707.4
OpenAlexW4249290481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.